The New York Entrepreneur

How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat Ashkenazi

Read Time:7 Second

Ashkenazi has been key to managing the windfall in revenue and wave of investor optimism from Eli Lilly’s diabetes injection Mounjaro and obesity drug Zepbound.

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post Oil prices hold ground after slowdown in China crude demand
Next post GameStop investors brace for rescheduled annual shareholder meeting